Over the past several years, FDA has issued several warning letters to firms that market unapproved new drugs that allegedly contain cannabidiol (CBD). As part of these actions, FDA has tested the chemical content of cannabinoid compounds in some of the products, and many were found to not contain the levels of CBD they claimed to contain. It is important to note that these products are not approved by FDA for the diagnosis, cure, mitigation, treatment, or prevention of any disease. Consumers should beware purchasing and using any such products.
Raphael Mechoulam – the organic chemist who discovered how THC interacts with our bodies – was the first to refer to this phenomenon of cannabinoids working more effectively together rather than in isolation. He coined the observation the ‘entourage effect’.
High quality CBD isolate has no other ingredients, additives or any other cannabinoids from the cannabis plant. While this can be it’s major advantage for those avoiding all traces of THC, it also means other beneficial cannabinoids from the cannabis plant are omitted.
The optimal CBD dose is the minimum amount required to feel desired effect.
‘Full spectrum’ is a term used to describe CBD products that, unlike isolate, contain a whole profile of other cannabinoids. Full spectrum products also include amounts of THC which are too small to feel, but potentially contribute to the effectiveness of CBD.
In the same vein as dabbing, vaping involves heating up a substance to a specific temperature and inhaling the vapor gases that are produced.
These use cases are further discussed below.
Most CBD isolate sold is flavourless, if you’re planning to take the sublingual approach, you may consider opting for a flavoured isolate product i.e.
Accessibility of CBD products was examined in the USA, Canada, Germany, Ireland, United Kingdom, Switzerland, Japan, Australia, and New Zealand as of May 2020. Regulatory and other relevant documents were obtained from government agency websites and related sources. Relevant commercial websites and some physical retailers were visited to verify access to CBD-containing products and the nature of the products available.
A range of CBD products appeared to be accessible without prescription in seven out of nine countries reviewed. Australia and New Zealand were the exceptions where clinician prescription was required to access any CBD-containing product. CBD products commonly available without prescription included oils, gel capsules, purified crystal and topical products. The daily recommended doses with orally administered non-prescription products were typically well below 150 mg and substantially lower than the doses reported to have therapeutic effects in published clinical trials (e.g., 300-1500 mg). The legal foundations enabling access in several countries were often unclear, with marketed products sometimes failing to meet legal requirements for sale. There was an obvious disparity between federal directives and available products in both the USA and European countries examined.
Recent legislative change has allowed increased access to cannabis products in many jurisdictions. In some locations, this includes over-the-counter (OTC) and/or online access to products containing cannabidiol (CBD), a non-intoxicating cannabinoid with therapeutic properties. Here we compared the availability of CBD products and the associated legislative and regulatory background in nine selected countries.
There are a variety of approaches in how countries manage access to CBD products. Many countries appear to permit OTC and online availability of CBD products but often without legislative clarity. As consumer demand for CBD escalates, improved legislation, guidelines and quality control of CBD products would seem prudent together with clinical trials exploring the therapeutic benefits of lower-dose CBD formulations.